Cancer Immunotherapy Market (Drugs & Therapeutics) to see Strong Growth to 2020

News provided by

May 06, 2015, 02:20 ET

DALLAS, May 6, 2015 /PRNewswire/ --

Global & USA Cancer Immunotherapy Market Analysis to 2020 is a 2015 research report that provides information on Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) and IDO Inhibitors.

Complete report on the cancer immunotherapy market spread across 256 pages providing company product portfolios for 78 pharma and biotech companies and supported with 114 tables and 41 figures is available at http://www.rnrmarketresearch.com/global-usa-cancer-immunotherapy-market-analysis-to-2020-market-report.html .

Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 11 chapters supported by 155 tables and figures over 256 pages. This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials.

The global cancer immunotherapy market is presented by the following sub-categories:

By Segment: Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies and Checkpoint Inhibitors.

By Product Segment: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors.

By Company: Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb and others.

An overview of products like I-Labelled Tositumomab (Bexxar), Y-Labelled Ibritumomab (Zevalin), Alemtuzumab (Campath), AdotrastuzumabEmtansine (Kadcyla), Bacillus Calmette-Guerin (BCG), Bevacizumab (Avastin), BrentuximabVedotin (Adcetris), Cetuximab (Erbitux), Cervarix, DenileukinDiftitox (Ontak), Gardasil, Gemtuzumab (Mylotarg), Hepatitis B Vaccine, Interferon Alfa (IFN-alfa), Interleukin-2 (IL-2), Ipilimumab (Yervoy), Ofatumumab (Arzerra), Panitumumab (Vectibix), Pembrolizumab (Keytruda), Rituximab (Mabthera), Sargramostim (Leukine), Sipuleucel-T (Provenge) and Trastuzumab (Herceptin) is provided in this research.

Companies like Ablynx NV, Activartis Biotech GmbH, Advaxis Inc., AduroBioTech Inc., Agenus Inc., AlphaVax Inc., A. MenariniIndustrieFarmaceuticheRiuniteSrl, Amgen Inc., Antigen Express Inc., Argos Therapeutics Inc., Bavarian Nordic A/S, Bellicum Pharmaceuticals Inc., Biogen Idec Inc., Biovest International Inc., Bristol-Myers Squibb Company, Cellectis, Cellerant Therapeutics Inc., Celldex Therapeutics, CEL-SCI Corp., CureTech Ltd., Delta-Vir GmbH, Dendreon Corp., DenDrit Biotech USA, DNAtrix Inc., Eli Lilly and Co., EMD Serono Inc., Etubics Corp. , Galena Biopharma Inc., Genentech Inc., Genmab AS, Gliknik Inc., GlobeImmune Inc., Heat Biologics Inc., Immatics Biotechnologies GmbH, ImmunoCellular Therapeutics Ltd., Immunocore Ltd., ImmunoFrontier Inc., ImmunoGen Inc., Immunomedics Inc., Immunotope Inc., Immunovaccine Inc., Inovio Pharmaceuticals Inc., Janssen Biotech Inc., Juno Therapeutics Inc., Kite Pharma Inc., MabVax Therapeutics Holdings Inc., MedImmune LLC, Merck & Co., Inc., Merrimack Pharmaceuticals Inc., Morphotek Inc., NewLink Genetics Corp., Northwest Biotherapeutics Inc., NovaRx Corp., OncoPep Inc., Oncothyreon Inc., OSE Pharma SA, Oxford BioTherapeutics Ltd., Pique Therapeutics, Polynoma LLC, Prima BioMed Ltd., Progenics Pharmaceuticals Inc., Regen Biopharma Inc., Roche Holdings Inc., Seattle Genetics Inc., Sorrento Therapeutics Inc., Spectrum Pharmaceuticals Inc., Synthon Pharmaceuticals Inc., TapImmune Inc., ThioLogics Ltd., Transgene SA, TVAX Biomedical Inc., Vaccinogen Inc., Viventia Biotechnologies Inc., Wilex AG and Ziopharm Oncology Inc. are profiled in this report.

Order a copy of Global & USA Cancer Immunotherapy Market Analysis to 2020 research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=349647 .

Key questions answered by this cancer immunotherapy market report include what are the three types of cancer immunotherapies? What are the immunotherapies approved between 1986 and 2014? What are the monoclonal antibodies (MAbs) approved by FDA to treat different types of cancers? What are naked MAbs and how many of them have been approved by FDA? What are antibody-drug conjugates (ADCs) and how many of them are available in the market? What are the common cytotoxic "warheads" used in ADCs? What are the important clinical assets in ADCs? How many bispecific MAbs are in late-stage development? What are the common side effects of MAbs in cancer immunotherapy? What are cancer vaccines and how many of them have been licensed to be marketed? How many cytokines have been approved for being used in cancer immunotherapy? What are the major checkpoint inhibitors in clinical development? What is the current status of anti-PD-1 drugs, dendritic cell therapies, T-cell therapies and cancer vaccines? What are the most valuable R&D projects in cancer immunotherapy and what would be their approximate sales revenues in 2020? Number of melanoma drugs approved between 1998 and 2014? Number of lung cancer drugs approved between 1998 and 2014? Number of brain cancer drugs approved between 1998 and 2014? What is the global market for cancer immunotherapeutics by geography, through 2020? What is the global market for cancer immunotherapeutics by product class such as MAbs, vaccines and non-specific immunotherapies, through 2020? What is the global market for cancer immunotherapeutics by indication, through 2020? What is the global market for MAbs by type such as naked MAbs and ADCs, through 2020? What are the market values for Herceptin, Avastin, Erbitux, Yervoy, Mabthera, Adectris, and Keytruda? What is the global market for cancer vaccines? What is the global market for cytokines in cancer immunotherapy? The projected market values for Nivolumab, RG7446, DCVax-L, MEDI4736 etc.

A related report on the cancer therapeutics market and cancer vaccine industry available with RnRMarketResearch.com includes:

Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies: This report focuses on the three principal types of therapeutics that have become the major focuses of research and development in cancer immunotherapy (which is often called "immuno-oncology") in recent years: Checkpoint inhibitors (discussed in Chapter 2), Therapeutic anticancer vaccines (discussed in Chapter 3) and Adoptive cellular immunotherapy (discussed in Chapter 4). The report also includes a survey on adoptive immunotherapy for cancer, which was conducted in conjunction with this report, and is discussed in Chapter 5. Also included are three expert interviews with the following people:

Adil Daud, MD, Clinical Professor, Department of Medicine (Hematology/Oncology), University of California at San Francisco (UCSF); Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center.
Matthew Lehman, Chief Executive Officer, Prima BioMed (a therapeutic cancer vaccine company with headquarters in Sydney, Australia).
Marcela Maus, MD, PhD, the Director of Translational Medicine and Early Clinical Development, Translational Research Program, Abramson Cancer Center, University of Pennsylvania in Philadelphia.

Complete report is available at http://www.rnrmarketresearch.com/cancer-immunotherapy-immune-checkpoint-inhibitors-cancer-vaccines-and-adoptive-t-cell-therapies-market-report.html .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]

Connect with Us:

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Market Research Blog: http://www.rnrmarketresearch.com/blog/

SOURCE RnR Market Research